Americord® is committed to pioneering the development of new cord blood, cord tissue, and placental tissue banking technologies. Under the leadership of Executive Medical Director, Dr. Robert Dracker, Americord® developed Cord Blood 2.0TM. This revolutionary extraction process harvests up to twice as many stem cells compared to a traditional cord blood collection.
As a rich source of Hematopoietic Stem Cells (HSCs), cord blood has a number of advantages, including decreased risk of severity of Graft-Versus-Host-Disease (GVHD) and a lower risk of transmissible infectious disease. However, the usefulness of cord blood in stem cell therapy has been limited by the relatively small amount of blood that can be collected using standard procedures. With Cord Blood 2.0TM, Americord® is making cord blood banking a lifelong investment with the possibility of treating patients well into adulthood.